Cellular reprogramming is an intrinsic evolutionary trait to constantly promote adaptations that confer survival advantage. It is also more frequent during development when organs are being formed and proteins required for plasticity are overexpressed.
Integration of the signals relies on the spatial-temporal distribution of the proteins within different signalling pathways and is the foundation of cell reprogramming. Internal and cell surface protein kinases and pseudokinases are major mediators of signal transduction, including kinases of the MAPK and PI3K pathways. Signalling switches between these pathways can be triggered by external or intracellular signals, including changes in the extracellular environment or errors occurring during mitosis. Moreover, reprogramming is an evolutionary process and is prone to errors itself.
Also, exposure to drug therapy often promotes cellular adaptations and changes that can lead to the development of mutations, and interfere with the expression, splicing, and post-translational modification of the protein kinases involved. These in turn can trigger the onset of pathologies, such as cancer, development defects and therapeutic failures.
The scope of this research topic is to gather a collection of research articles, reviews, brief research reports, and opinion letters that explore the latest findings in the reprogramming of signalling pathways focusing on protein kinases, pseudo kinases and Kinase inhibitors. We also aim for studies where signalling switches occur in response to target therapies.
Cellular reprogramming is an intrinsic evolutionary trait to constantly promote adaptations that confer survival advantage. It is also more frequent during development when organs are being formed and proteins required for plasticity are overexpressed.
Integration of the signals relies on the spatial-temporal distribution of the proteins within different signalling pathways and is the foundation of cell reprogramming. Internal and cell surface protein kinases and pseudokinases are major mediators of signal transduction, including kinases of the MAPK and PI3K pathways. Signalling switches between these pathways can be triggered by external or intracellular signals, including changes in the extracellular environment or errors occurring during mitosis. Moreover, reprogramming is an evolutionary process and is prone to errors itself.
Also, exposure to drug therapy often promotes cellular adaptations and changes that can lead to the development of mutations, and interfere with the expression, splicing, and post-translational modification of the protein kinases involved. These in turn can trigger the onset of pathologies, such as cancer, development defects and therapeutic failures.
The scope of this research topic is to gather a collection of research articles, reviews, brief research reports, and opinion letters that explore the latest findings in the reprogramming of signalling pathways focusing on protein kinases, pseudo kinases and Kinase inhibitors. We also aim for studies where signalling switches occur in response to target therapies.
